VCNX Vaccinex Inc.

5.11
0  0%
Previous Close 5.11
Open
Price To Book -3.32
Market Cap 58,656,888
Shares 11,478,843
Volume 0
Short Ratio
Av. Daily Volume 11,337

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 cohort A data to be published 2H 2019, cohort B top-line data due 2H 2020.
VX15 - Signal
Huntington’s disease
Phase 1/2 trial to be completed 2H 2020.
VX15 Yervoy and Opdivo
Melanoma
Phase 1/2 trial to be completed 2H 2019.
VX15 and avelumab
Non-small cell lung cancer (NSCLC)

Latest News

  1. Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
  2. Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
  3. Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
  4. Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
  5. Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
  6. Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
  7. Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
  8. Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
  9. Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
  10. Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial
  11. Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)?
  12. Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research
  13. Vaccinex, Inc. to Present at the 11th Annual LD Micro Main Event
  14. Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting
  15. Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  16. Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting
  17. Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease